UY31496A1 - Agonistas novedosos de los receptores de glucocorticoides - Google Patents

Agonistas novedosos de los receptores de glucocorticoides

Info

Publication number
UY31496A1
UY31496A1 UY31496A UY31496A UY31496A1 UY 31496 A1 UY31496 A1 UY 31496A1 UY 31496 A UY31496 A UY 31496A UY 31496 A UY31496 A UY 31496A UY 31496 A1 UY31496 A1 UY 31496A1
Authority
UY
Uruguay
Prior art keywords
glucocorticoid receptors
new agonists
relates
present
agonists
Prior art date
Application number
UY31496A
Other languages
English (en)
Inventor
Paul Alan Glossop
David Simon Millan
David Anthony Price
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31496A1 publication Critical patent/UY31496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a agonistas novedosos del receptor de glucocorticoides de la formula (|): y a procedimientos e intermedios para su preparacion. La presente invencion también se refiere a composiciones farmacéuticas que contienen estos compuestos, a su combinacion con otro u otros agentes terapéuticos, así como a su uso para el tratamiento de un numero de enfermedades, trastornos y afecciones inflamatorios y alérgicos.
UY31496A 2007-11-30 2008-11-28 Agonistas novedosos de los receptores de glucocorticoides UY31496A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10

Publications (1)

Publication Number Publication Date
UY31496A1 true UY31496A1 (es) 2009-07-17

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31496A UY31496A1 (es) 2007-11-30 2008-11-28 Agonistas novedosos de los receptores de glucocorticoides

Country Status (32)

Country Link
US (2) US8822439B2 (es)
EP (1) EP2225256B1 (es)
JP (1) JP4686650B2 (es)
KR (1) KR101295998B1 (es)
CN (1) CN101878221B (es)
AP (1) AP2010005267A0 (es)
AR (1) AR069490A1 (es)
AU (1) AU2008331187B2 (es)
BR (1) BRPI0820447A2 (es)
CA (1) CA2706180C (es)
CL (1) CL2008003549A1 (es)
CO (1) CO6280401A2 (es)
CR (1) CR11393A (es)
DK (1) DK2225256T3 (es)
DO (1) DOP2010000161A (es)
EA (1) EA201070535A1 (es)
EC (1) ECSP10010209A (es)
ES (1) ES2399945T3 (es)
GT (1) GT201000153A (es)
IL (1) IL205356A0 (es)
MA (1) MA31867B1 (es)
MX (1) MX2010005861A (es)
NI (1) NI201000090A (es)
NZ (1) NZ585434A (es)
PA (1) PA8805801A1 (es)
PE (1) PE20091072A1 (es)
SV (1) SV2010003580A (es)
TN (1) TN2010000230A1 (es)
TW (1) TW200930378A (es)
UY (1) UY31496A1 (es)
WO (1) WO2009069032A2 (es)
ZA (1) ZA201003439B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087946A1 (en) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
BR112013022890A2 (pt) 2011-03-15 2016-09-13 Chiesi Farma Spa composto, composição farmacêutica, combinação e uso de um composto
MX345400B (es) * 2011-03-15 2017-01-30 Chiesi Farm Spa Derivados de isoxazolidina.
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA2906029C (en) * 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3244893A4 (en) * 2015-02-18 2019-01-09 Parion Sciences, Inc. SODIUM CHANNEL BLOCKER FOR SKIN DISEASES
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019106608A1 (en) * 2017-12-01 2019-06-06 Abbvie Inc. Anti-cd40 antibody drug conjugates
BR112020010694A2 (pt) * 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
WO2019180150A1 (en) 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
CN117580849A (zh) * 2021-06-24 2024-02-20 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
CN120463762A (zh) * 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
KR102835682B1 (ko) * 2022-06-16 2025-07-22 애브비 바이오테라퓨틱스 인크. 항-cd19 항체-약물 접합체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
AU2003301516A1 (en) 2002-10-24 2004-05-13 Goldstein, Jay A Antifungal formulations
WO2005044759A2 (en) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
CN101878221A (zh) 2010-11-03
CA2706180A1 (en) 2009-06-04
US20140336160A1 (en) 2014-11-13
HK1144821A1 (en) 2011-03-11
EP2225256A2 (en) 2010-09-08
BRPI0820447A2 (pt) 2015-05-26
AU2008331187A1 (en) 2009-06-04
DOP2010000161A (es) 2010-07-15
GT201000153A (es) 2012-04-27
JP4686650B2 (ja) 2011-05-25
KR101295998B1 (ko) 2013-08-13
DK2225256T3 (da) 2013-03-11
CN101878221B (zh) 2014-04-02
EP2225256B1 (en) 2013-01-09
CR11393A (es) 2010-05-19
NZ585434A (en) 2012-06-29
US20090227548A1 (en) 2009-09-10
CA2706180C (en) 2012-10-23
CL2008003549A1 (es) 2009-11-20
MX2010005861A (es) 2010-06-11
ZA201003439B (en) 2011-02-23
AU2008331187B2 (en) 2014-04-03
US8822439B2 (en) 2014-09-02
TW200930378A (en) 2009-07-16
CO6280401A2 (es) 2011-05-20
TN2010000230A1 (fr) 2011-11-11
AR069490A1 (es) 2010-01-27
ES2399945T3 (es) 2013-04-04
SV2010003580A (es) 2011-03-23
ECSP10010209A (es) 2010-06-29
MA31867B1 (fr) 2010-11-01
PA8805801A1 (es) 2009-07-23
EA201070535A1 (ru) 2010-12-30
WO2009069032A2 (en) 2009-06-04
AP2010005267A0 (en) 2010-06-30
PE20091072A1 (es) 2009-07-23
IL205356A0 (en) 2010-12-30
WO2009069032A3 (en) 2009-08-06
NI201000090A (es) 2010-10-04
KR20100074306A (ko) 2010-07-01
JP2011505350A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
UY31496A1 (es) Agonistas novedosos de los receptores de glucocorticoides
UY32675A (es) Nuevos agonistas del receptor de glucocorticoides
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
PA8632801A1 (es) Derivados de tetrahidronaftiridina
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
UY30292A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
SV2008003037A (es) Derivados de amina
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
CR9814A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR20190379A (es) Moduladores del receptor de estrógeno
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CO2021001174A2 (es) Inhibidores de ckd8/19
CU20090083A7 (es) Análogos de pirazol
UY28911A1 (es) Profármacos de esteroides con acción androgénica
CU20100110A7 (es) Agonistas novedosos de los receptores de glucocorticoides
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UA95861C2 (en) Glucocorticoid receptor agonists
UY32718A (es) Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011